Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)

A Phase 1 clinical trial evaluating an investigational vaccine against SARS-CoV-2, known as mRNA-1273, is being conducted in Seattle, Atlanta and the NIH Clinical Center in Bethesda, Maryland. Launched in March 2020, the trial is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response. The vaccine candidate was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc. This is the first of multiple steps in the clinical research process for evaluating the potential benefit of the vaccine. For more information, visit using identifier NCT04283461.

Enrollment of 45 healthy adult volunteers ages 18 to 55 is now complete, so investigators are no longer seeking volunteers ages 18 to 55 for this trial. The trial was recently expanded to enroll 30 adults ages 56 to 70 years and 30 adults ages 71 years and older. Contact information is below for adults over the age of 55 in the Atlanta, Bethesda or Seattle areas who are interested in joining this study.

Contact Information

Participating in Research

Watch a series of short informational videos about participating in clinical trials. These videos are intended to help potential participants understand how research works, what questions they should consider asking, and things to think about when deciding whether or not to participate in a study.

Content last reviewed on